Amarin (NASDAQ:AMRN) Rating Increased to Buy at Wall Street Zen

Amarin (NASDAQ:AMRN) was upgraded by research analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Sunday.

AMRN has been the subject of a number of other reports. Zacks Research upgraded shares of Amarin from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, June 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Amarin in a research report on Monday, April 20th. One investment analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy”.

Amarin Trading Down 1.6%

NASDAQ:AMRN traded down $0.24 during mid-day trading on Friday, reaching $14.88. The company’s stock had a trading volume of 74,753 shares, compared to its average volume of 84,694. The stock has a market cap of $312.03 million, a P/E ratio of -22.89 and a beta of 0.80. The firm’s fifty day moving average price is $15.05 and its two-hundred day moving average price is $14.86. Amarin has a 12-month low of $12.96 and a 12-month high of $20.90.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. GAMMA Investing LLC grew its stake in shares of Amarin by 197.4% during the 2nd quarter. GAMMA Investing LLC now owns 1,576 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 1,046 shares during the period. Banque Cantonale Vaudoise purchased a new stake in shares of Amarin during the 3rd quarter valued at about $32,000. Brooklands Fund Management Ltd bought a new position in shares of Amarin in the 4th quarter worth approximately $42,000. Headlands Technologies LLC purchased a new position in shares of Amarin in the second quarter worth approximately $44,000. Finally, Northwestern Mutual Wealth Management Co. grew its position in Amarin by 1,816.7% during the third quarter. Northwestern Mutual Wealth Management Co. now owns 5,750 shares of the biopharmaceutical company’s stock valued at $94,000 after buying an additional 5,450 shares during the period. Institutional investors own 22.25% of the company’s stock.

About Amarin

Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics for cardiovascular health. Founded in 1993 and headquartered in Dublin, Ireland, the company is publicly traded on the NASDAQ under the ticker AMRN. Amarin’s primary mission is to improve cardiovascular outcomes through innovative lipid science and evidence-based therapies.

The company’s flagship product is Vascepa® (icosapent ethyl), a high-purity prescription omega-3 fatty acid approved for the treatment of severe hypertriglyceridemia and as an adjunct to statin therapy to reduce the risk of cardiovascular events.